‘Opioids’ Is Missing From The US FDA’s Overdose Prevention Framework Title On Purpose
Executive Summary
Unlike prior plans, the FDA’s new substance abuse framework is intended to deal with stimulant and benzodiazepine use disorders, in addition to opioid abuse.
You may also be interested in...
New Opioid Labeling Further Constrains Use, Urges Prescribing Only By Docs ‘Knowledgeable’ About Risks
US FDA’s mandated labeling changes come after the agency required manufacturers to provide mail-back envelopes for opioid disposal.
‘Thanks For Calling The FDA. This Is A Computer’… AI Could Help Field Drug Safety Questions
The agency is considering using artificial intelligence, including chat bots, to deal with telephone calls from the public about drug safety issues.
Califf Urges Congressional Patience On Opioid Actions
Labeling changes for the pain products remain in active discussion, the US FDA commissioner tells the Senate Health, Education, Labor and Pensions Committee during a hearing on the monkeypox outbreak.